(Q44364104)

English

A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors

scientific article published on 4 January 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

J B Vermorken

1

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

S Rottey

2

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

E Ehrnrooth

3

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

K Pelling

4

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

A Lahogue

5

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

S Wind

6

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

J-P Machiels

7

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

publication date

4 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

1392-1400

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS633

21 January 2018

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS633

21 January 2018

EGF-ERBB signalling: towards the systems level

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS633

21 January 2018

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS633

21 January 2018

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS633

21 January 2018

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS633

21 January 2018

Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS633

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS633

21 January 2018

Hematological side-effect profiles of individualized chemotherapy regimen for recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS633

21 January 2018

Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS633

21 January 2018

Epidermal growth factor receptor (EGFR) signaling in cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS633

21 January 2018

Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS633

21 January 2018

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS633

21 January 2018

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS633

21 January 2018

EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS633

21 January 2018

Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS633

21 January 2018

Identifiers

10.1093/ANNONC/MDS633

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44364104&oldid=2020101751"